Shi Peiying, Ruan Yijun, Zhong Chenhui, Teng Linglin, Ke Liyuan, Yao Hong
Department of Traditional Chinese Medicine Resource and Bee Products, College of Animal Sciences (College of Bee Science), Fujian Agriculture and Forestry University, Fuzhou, China.
State and Local Joint Engineering Laboratory of Natural Biotoxins, Fujian Agriculture and Forestry University, Fuzhou, China.
Front Pharmacol. 2022 Nov 23;13:1062026. doi: 10.3389/fphar.2022.1062026. eCollection 2022.
Safflower injection (SI), a water-extract preparation from safflower ( L.), has been widely used for the treatment of cardio-cerebrovascular diseases. This work aims to develop an approach for identifying PK markers of cardiovascular herbal medicines using SI as a case study. Firstly, qualitative and quantitative analyses were performed to reveal ingredients of the preparation HPLC-MS. Subsequently, multiple PK ingredients and integrated PK investigations were carried out to ascertain ingredients with favorable PK properties (e.g., easily detected at conventional PK time points and high system exposure) for the whole preparation. Next, ingredients against cardiovascular diseases (CVDs) in the preparation were predicted with target fishing and system pharmacology studies. Finally, ingredients with favorable PK properties, satisfactory PK representativeness for the preparation, and high relevance to CVDs were considered as potential PK markers. Their therapeutic effect was further evaluated using the HO-induced H9c2 cardiomyocyte-injured model and a proteomics study to identify objective PK markers. As results, it disclosed that SI mainly contains 11 ingredients. Among them, five ingredients, namely, hydroxysafflor yellow A (HSYA), syringin (SYR), -coumaric acid (-CA), scutellarin (SCU), and -hydroxybenzaldehyde (-HBA), showed favorable PK properties. HSYA, SYR, and rutin (RU) were predicted to show high relevance to CVDs and screened as potential PK markers. However, only HSYA and SYR were confirmed as therapeutic ingredients against CVDs. Combined with these findings, only HSYA demonstrated satisfactory representativeness on PK properties and therapeutic effects of multiple ingredients of the preparation, thereby indicating that HSYA is a potential PK marker for the SI. The results of this study can provide a reference for the characterization of PK markers for traditional Chinese medicines.
红花注射液(SI)是一种从红花中提取的水制剂,已被广泛用于治疗心脑血管疾病。本研究旨在以SI为例,开发一种识别心血管类草药药物药代动力学(PK)标志物的方法。首先,采用高效液相色谱 - 质谱联用(HPLC-MS)进行定性和定量分析,以揭示该制剂的成分。随后,进行了多种PK成分和综合PK研究,以确定整个制剂中具有良好PK特性(如在常规PK时间点易于检测且系统暴露量高)的成分。接下来,通过靶点筛选和系统药理学研究预测制剂中抗心血管疾病(CVD)的成分。最后,将具有良好PK特性、对制剂具有令人满意的PK代表性且与CVD高度相关的成分视为潜在的PK标志物。使用过氧化氢(HO)诱导的H9c2心肌细胞损伤模型和蛋白质组学研究进一步评估它们的治疗效果,以识别客观的PK标志物。结果表明,SI主要含有11种成分。其中,羟基红花黄色素A(HSYA)、紫丁香苷(SYR)、对香豆酸(-CA)、灯盏花乙素(SCU)和对羟基苯甲醛(-HBA)这五种成分具有良好的PK特性。预测HSYA、SYR和芦丁(RU)与CVD高度相关,并被筛选为潜在的PK标志物。然而,只有HSYA和SYR被确认为抗CVD的治疗成分。综合这些发现,只有HSYA在制剂多种成分的PK特性和治疗效果方面表现出令人满意的代表性,从而表明HSYA是SI的潜在PK标志物。本研究结果可为中药PK标志物的表征提供参考。